BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance

BIOMARIN PHARMACEUTICAL INC

2025-Q2 EPS reported $2.19 revenue$1,570,555,000

Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).
Non-GAAP diluted EPS $1.44 (+50%); N-GAAP operating margin 39.9% (up 8.7pp Y/Y).
VOXZOGO revenue $221M (+20%) and Enzyme Therapies $555M (+15%); KUVAN down 7% to $27M.
Raised FY2025 guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.
Completed Inozyme acquisition (July); BMN 333 (achondroplasia) Phase 2/3 to start 1H'26; BMN 390 discontinued.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.